Amryt On Targeting Rare Disease Space In The Middle East

The rare and orphan drug company Amryt speaks to the Pink Sheet about how to do business in the Middle East and why seeking marketing authorization could be a better long-term strategy than catering for named patient requests.

Middle east
Amryt has set its sights on the Middle East. • Source: Shutterstock

Amryt Pharma, a company with ambitions to become a leader in the rare disease space, has set its sights on the Middle East. David Allmond, the company’s chief commercial officer spoke to the Pink Sheet about the advantages of marketing authorization, the benefits of local partners and how to get the value proposition right for the payer.

Lojuxta (lomitapide), a treatment for adults with homozygous familial hypercholesterolemia (HoFH), a rare and life-threatening condition that impairs the body's...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet